OriGene Technologies, Inc., a leading gene-centric life sciences company, and the Institute for Systems Biology (ISB), announce plans to create a proteotypic PeptideAtlas and develop an SRM/MRM (single reaction monitoring, multiple reaction monitoring) mass spectrometry standard database for 5,000 human proteins. The new collaboration will apply ISB's novel systems biology mass spectrometry expertise to OriGene's large collection of full length human proteins.
Proteomics research and biomarker development hold great promise in personalized medicine. Mass spectrometry, especially SRM/MRM, has emerged as a new platform for simultaneous quantitative characterization of multiple proteins, thus making it an ideal choice for high throughput proteomics and clinical biomarker research. SRM/MRM is widely used for biomarker identification and quantification, especially when there is no suitable ELISA pair for targets under investigation. Creating the proteotypic PeptideAtlas and SRM/MRM mass spectrometry standard database for 5,000 human proteins will enable quantitative protein analysis and facilitate lab-to-lab data validation.
"The field of proteomics combined with systems biology will push discovery further, but it is essential to validate these discoveries with a large scale mass spectrometry standard database," said Leroy Hood, M.D., Ph.D., ISB's President and co-founder. Dr. Hood continued, "By providing ISB with access to one of the largest collections of full length human protein in the world, this collaboration will rapidly accelerate the validation of ISB's discoveries."
"This is the first time a 5,000 human protein mass spectrometry standard database will be used to advance and accelerate medical research," said Wei-Wu He, OriGene's Chairman and CEO. Dr. He continued, "We are excited to be able to integrate ISB's substantial experience in mass spectrometry with our database and look forward to working with Dr's. Hood and Moritz and their renowned team at ISB to develop early diagnostic tools and treatment solutions for human disease. This unprecedented joint effort of creating a proteotypic PeptideAtlas and SRM/MRM mass spectrometry standard database for 5,000 human proteins will provide extremely important information for the SRM/MRM research community. Undoubtedly it will also speed up the pace of its application in novel biomarker discovery."
SOURCE OriGene Technologies, Inc.